RxDoctor Payments Data

Bradley Rosenberg, MD

Neurology · Covina, CANPI 1477512069

Payments from drug & device makers

$744in general payments, 2019–2025

Across 31 payments — averaging $23.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$193
  • Livanova USA, Inc.$136
  • Abbott$90
  • Lilly USA, LLC$60
  • AbbVie$48
  • Amgen$47
  • plus $169 from 8 others

What the payments were for

  • Food & beverage$69994%
  • Education$456%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
UCB, Inc.8$193
Livanova USA, Inc.1$136
Abbott4$90
Lilly USA, LLC3$60
AbbVie(2 entities)3$48
Amgen2$47
Strongbridge US Inc.2$33
AstraZeneca1$28
Sunovion Pharmaceuticals Inc.2$28
Neurocrine Biosciences, Inc.1$20
Biogen1$19
Novartis1$16
GSK1$14
Zyla Life Sciences, Inc.1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$744 in reported general payments places this provider in the 45th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$90,652
Medicare patients
299
Services billed
5,036

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5030$305,754
CopaxoneGlatiramer Acetate22$124,884
Avonex (4 Pack)Interferon Beta-1a13$104,923
Teriflunomide11$49,979
AptiomEslicarbazepine Acetate11$31,874
KeppraLevetiracetam11$22,765
Carbidopa-LevodopaCarbidopa/Levodopa374$9,587
Levetiracetam188$7,322
Carbamazepine ErCarbamazepine35$5,914
Lacosamide51$5,841
Entacapone37$5,554
Divalproex Sodium ErDivalproex Sodium45$4,223
Clobazam13$3,993
Rivastigmine12$2,875
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen101$2,778

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenAvonex (4 Pack)$19$104,92313 claims
Sunovion Pharmaceuticals Inc.Aptiom$28$31,87411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,996 neurology providers in California.

Other neurology in Covina

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →